QLSF Biotherapeutics is an innovative immuno-oncology startup company based in South San Francisco. With a strong focus on developing next-generation antibody-based therapeutics, their diversified oncology portfolio aims to address challenging targets for the treatment of cancer.
Supported by a leading pharmaceutical company, QLSF Biotherapeutics is dedicated to advancing their pipeline of novel T cell engagers and bispecific antibodies. Their ongoing Phase 1 trials for QL325 and QL335 show promising potential in targeting acute myeloid leukemia and colorectal cancer, respectively.
Generated from the website